M&T BANK CORP - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 290 filers reported holding INTRA CELLULAR THERAPIES INC in Q3 2023. The put-call ratio across all filers is 1.03 and the average weighting 0.2%.

Quarter-by-quarter ownership
M&T BANK CORP ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$208,506
-36.3%
4,006
-22.6%
0.00%0.0%
Q2 2023$327,411
+7.3%
5,174
-8.3%
0.00%0.0%
Q1 2023$305,125
-54.8%
5,643
-64.2%
0.00%0.0%
Q4 2022$674,672
+146.2%
15,767
+167.8%
0.00%0.0%
Q3 2022$274,000
+29.9%
5,888
+59.5%
0.00%0.0%
Q2 2022$211,000
-34.5%
3,692
-29.7%
0.00%0.0%
Q1 2022$322,000
-9.6%
5,252
-22.8%
0.00%0.0%
Q4 2021$356,000
+41.8%
6,804
+1.2%
0.00%0.0%
Q3 2021$251,000
-15.5%
6,722
-7.6%
0.00%0.0%
Q2 2021$297,000
+24.3%
7,271
+3.6%
0.00%0.0%
Q1 2021$239,000
-31.3%
7,015
-36.0%
0.00%
-50.0%
Q4 2020$348,000
-32.8%
10,953
-45.7%
0.00%
-33.3%
Q3 2020$518,000
+18.0%
20,176
+18.0%
0.00%
+50.0%
Q2 2020$439,000
+143.9%
17,105
+45.7%
0.00%
+100.0%
Q1 2020$180,000
-45.5%
11,736
+42.3%
0.00%
-50.0%
Q3 2015$330,0008,2500.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q3 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 175,000$9,115,75010.70%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 317,856$16,547,5835.57%
Deep Track Capital, LP 2,600,000$135,434,0005.23%
SUVRETTA CAPITAL MANAGEMENT, LLC 1,369,849$71,355,4343.86%
SILVERARC CAPITAL MANAGEMENT, LLC 208,730$10,872,7463.30%
DCF Advisers, LLC 107,157$5,581,8083.04%
Bellevue Group AG 3,170,250$165,138,3232.66%
Vahanian & Associates Financial Planning Inc. 15,217$792,6542.55%
Iron Triangle Partners LP 330,549$17,218,2972.52%
TANG CAPITAL MANAGEMENT LLC 300,000$15,627,0002.20%
View complete list of INTRA CELLULAR THERAPIES INC shareholders